Allergan plc (AGN)
(Delayed Data from NYSE)
$145.81 USD
+1.56 (1.08%)
Updated May 3, 2019 04:01 PM ET
After-Market: $145.88 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$145.81 USD
+1.56 (1.08%)
Updated May 3, 2019 04:01 PM ET
After-Market: $145.88 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Amgen's Repatha Gains CHMP Nod to Include Outcomes Data
by Zacks Equity Research
Amgen (AMGN) gets CHMP's positive opinion to incorporate a new indication into the European label of its PCSK9 inhibitor, Repatha.
AbbVie's Uterine Fibroids Candidate Succeeds in Phase III
by Zacks Equity Research
AbbVie (ABBV) and partner Neurocrine Biosciences announce that the second of the two pivotal phase III studies evaluating elagolix, met the primary endpoint for treating women with uterine fibroids.
The Zacks Analyst Blog Highlights: Lockheed Martin, Allergan, Barclays, Constellation Brands and Southwest Airlines
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Lockheed Martin, Allergan, Barclays, Constellation Brands and Southwest Airlines
Why Is Allergan (AGN) Down 10.1% Since its Last Earnings Report?
by Zacks Equity Research
Allergan (AGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Aerie's (AERI) Q4 Loss Wider on Higher Operating Expenses
by Zacks Equity Research
Aerie (AERI) incurs a wider-than-expected loss in the fourth quarter due to higher operating expenses.
Abbvie's Uterine Fibrosis Candidate Meets Goal in Study
by Zacks Equity Research
AbbVie's (ABBV) phase III study of its late stage candidate elagolix meets its primary endpoint in women with uterine fibroids.
Teva's Problems Continue to Mount With No Relief in Sight
by Zacks Equity Research
Teva (TEVA) faces significant challenges including rapid erosion in sales of Copaxone and pricing erosion in the U.S. generics business.
Ironwood (IRWD) Beats Estimates in Q4 Earnings, Stock Up
by Zacks Equity Research
Ironwood Pharmaceuticals (IRWD) beats estimates on both counts in the fourth quarter. Demand for Linzess continues to rise.
Teva (TEVA) Q4 Earnings Top, Stock Tanks on Weak 2018 View
by Zacks Equity Research
Teva's (TEVA) fourth-quarter earnings and sales beat expectations. However, the 2018 sales and earnings outlook falls short of consensus estimate.
Allergan (AGN) Q4 Earnings Beat on Increase in Botox Sales
by Zacks Equity Research
Allergan (AGN) beats expectations for both earnings and revenues in Q4. A phase III study evaluating Allergan's migraine candidate, ubrogepant meets its co-primary endpoints.
Allergan (AGN) Beats Q4 Earnings & Sales, Stock Up
by Zacks Equity Research
Allergan (AGN) beats expectations for both earnings and revenues in Q4. A phase III study evaluating Allergan's migraine candidate, ubrogepant meets its co-primary endpoints.
Teva Completes Sale of Women's Health Segment for $703M
by Zacks Equity Research
Teva Pharmaceutical (TEVA) sells woman health specialty products for cash consideration of $703 million.
Allergan's Anti-Infective Drug Avycaz Receives Third FDA Nod
by Zacks Equity Research
The FDA's label expansion approval for Allergan's (AGN) Avycaz marks its third therapeutic indication nod for the anti-infective drug in the United States.
Allergan (AGN) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
While Allergan's (AGN) Q4 sales are likely to be driven by new as well as established products like Botox and international growth, generic competition for some key products will hurt sales.
Amgen's Migraine Drug Hits Primary Endpoint in Phase IIIb
by Zacks Equity Research
Amgen's (AMGN) antibody Aimovig meets all primary and secondary endpoints in a phase IIIb study on patients with episodic migraine, who have failed multiple prior preventive treatments.
Teva's Asthma Therapy Reslizumab Fails in Late-Stage Studies
by Zacks Equity Research
Teva's (TEVA) two phase III studies evaluating the subcutaneous formulation of its asthma injection, Cinqair (reslizumab) fail to meet primary endpoints.
Amgen/Allergan's Avastin Biosimilar Secures EU Approval
by Zacks Equity Research
Amgen (AMGN) and Allergan's Mvasi - a biosimilar version of Roche's cancer drug, Avastin - gets marketing approval in the EU.
Cancer Space Update: Label Expansions, Data Readouts in Focus
by Zacks Equity Research
This week the cancer space was abuzz with news of label expansion of Kyprolis, Lynparza and Kymriah and positive data readouts for Cabometyx and Keytruda.
Teva's Trisenox Gets FDA Approval as First-Line Treatment
by Zacks Equity Research
Teva Pharmaceutical (TEVA) receives approval from the FDA for label expansion of its leukemia drug, Trisenox, in first-line setting.
Will Amgen (AMGN) Continue to Tread Growth Path This Year?
by Zacks Equity Research
Amgen (AMGN) stock outperformed the industry in 2017. We will have to wait and see if it can keep the momentum alive in 2018.
Big Pharma CEOs Speak About Impact of Tax Reform on M&A
by Zacks Equity Research
This week, senior executives of some large drug companies discussed the impact of tax reform on mergers and acquisition and their plans to use the excess cash at the JP Morgan HealthCare conference.
Allergan's (AGN) Sales Guidance for 2018 Lower Than Expected
by Zacks Equity Research
Allergan (AGN) announces weaker-than-expected sales outlook for 2018. A generic version of Restasis is expected to be launched in Q2.
Key Biosimilar Approvals in 2017: Progress Report
by Zacks Equity Research
The biosimilar space was much in focus as the FDA approved a few biosimilars for key blockbuster drugs. We expect investor focus on the same in 2018 as well.
Allergan to Cut Jobs Amid Loss of Exclusivity for Key Drugs
by Zacks Equity Research
Allergan (AGN) is laying off over 1,000 employees as part of a cost-cutting and restructuring program as it faces potential loss of exclusivity for some of its key products in 2018.
Valeant (VRX) to Settle Allergan Litigation for $290 Million
by Zacks Equity Research
Valeant (VRX) and Pershing Square decided to resolve the claims of the long standing Allergan lawsuit for $290 million. Valeant will now pay 33% of the costs, down from the previous agreement of 60%.